Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23831139 | 0.88 | KCNH2 (0.48) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL31434521 | 0.81 | CYP11B1 (0.42) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL17102309 | 0.76 | LMNA (0.64) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL5533142 | 0.75 | CYP11B1 (0.49) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL26129994 | 0.74 | CYP11B1 (0.47) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL31447581 | 0.73 | CYP1A2 (0.38) | CYP19A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23120688 | 0.73 | HSP90AA1 (0.48) | HSP90AA1HSP90B1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL30196060 | 0.73 | AGTR2 (0.41) | CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL697931 | 0.72 | KMT2A (0.40) | HSP90AA1CYP11B1CYP11B2LMNAMEN1 | |
| SCHEMBL26128312 | 0.72 | KCNH2 (0.48) | CYP11B1CYP11B2CYP19A1LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441718-B2 | Selective angiotensin II compounds | VICORE PHARMA AB (SE) | 2025-10-14 | — | — | US | disclosed |
| US-20250101010-A1 | SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2025-03-27 | — | — | US | disclosed |
| WO-2025044926-A1 | THIENYLSULFONYL CARBAMATES AS AT2R AGONISTS | 武汉人福创新药物研发中心有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119504723-A | Thiophene sulfonyl carbamates as AT2R agonists | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240262813-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2024-08-08 | — | — | US | disclosed |
| CN-117916229-A | Novel selective angiotensin II compounds | 维科尔药物公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023281271-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262813-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | AGTR1, AGTR2, REN | HSP90AA1 4547/4885HSP90B1 4554/4885CYP11B1 251/4885 |
| US-20250101010-A1 | SELECTIVE ANGIOTENSIN II COMPOUNDS | AGTR1, AGTR2, REN | HSP90AA1 4609/4885HSP90B1 4542/4885CYP11B1 200/4885 |
| US-12441718-B2 | Selective angiotensin II compounds | AGTR1, AGTR2, REN | HSP90AA1 4609/4885HSP90B1 4542/4885CYP11B1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.